Elucidating the specific pharmacological mechanism of action (MOA) of naturally developing compounds can be tough. Although Tarselli et al. (60) created the very first de novo synthetic pathway to conolidine and showcased this naturally taking place compound proficiently suppresses responses to each chemically induced and inflammation-derived pain,